Alkermes plc. Contract with Customer, Asset, Purchase
Alkermes plc. (ALKS) reported Contract with Customer, Asset, Purchase of $4.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Credit Losses
us-gaap:ContractWithCustomerAssetPurchase · last filed 2026-02-25
- Alkermes plc. contract with customer, asset, purchase for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Alkermes plc. contract with customer, asset, purchase for the quarter ending 2025-09-30 was $717.00K, a 55.82% decline year-over-year.
- Alkermes plc. contract with customer, asset, purchase for the quarter ending 2025-06-30 was $717.00K, a 79.47% decline year-over-year.
- Alkermes plc. contract with customer, asset, purchase for the quarter ending 2025-03-31 was $3.05M, a 148.09% increase year-over-year.
- Alkermes plc. contract with customer, asset, purchase for fiscal 2025 was $4.48M, a 32.23% decline from fiscal 2024.
- Alkermes plc. contract with customer, asset, purchase for fiscal 2024 was $6.62M, a 51.38% decline from fiscal 2023.
- Alkermes plc. contract with customer, asset, purchase for fiscal 2023 was $13.61M, a 67.77% decline from fiscal 2022.
- Alkermes plc. contract with customer, asset, purchase for fiscal 2022 was $42.22M.
| Period end | Contract with Customer, Asset, Purchase 3 month | Contract with Customer, Asset, Purchase 6 month | Contract with Customer, Asset, Purchase 9 month | Contract with Customer, Asset, Purchase 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $717.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.43M derived: sum of 3 quarters · filed 2026-02-25 | $4.48M 10-K · filed 2026-02-25 |
| 2025-09-30 | $717.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $1.43M derived: sum of 2 quarters · filed 2025-10-28 | $4.48M 10-Q · filed 2025-10-28 | $4.75M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-06-30 | $717.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $3.77M 10-Q · filed 2025-07-29 | $4.04M derived: sum of 3 quarters · filed 2026-02-25 | $5.66M derived: sum of 4 quarters · filed 2026-02-25 |
| 2025-03-31 | $3.05M 10-Q · filed 2025-05-01 | $3.32M derived: sum of 2 quarters · filed 2026-02-25 | $4.94M derived: sum of 3 quarters · filed 2026-02-25 | $8.44M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-12-31 | $271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.89M derived: sum of 2 quarters · filed 2026-02-25 | $5.39M derived: sum of 3 quarters · filed 2026-02-25 | $6.62M 10-K · filed 2026-02-25 |
| 2024-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-24 | $5.12M derived: sum of 2 quarters · filed 2024-10-24 | $6.34M 10-Q · filed 2024-10-24 | $7.07M derived: sum of 4 quarters · filed 2025-02-12 |
| 2024-06-30 | $3.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-24 | $4.72M 10-Q · filed 2024-07-24 | $5.45M derived: sum of 3 quarters · filed 2025-02-12 | $8.21M derived: sum of 4 quarters · filed 2025-02-12 |
| 2024-03-31 | $1.23M 10-Q · filed 2024-05-01 | $1.95M derived: sum of 2 quarters · filed 2025-02-12 | $4.72M derived: sum of 3 quarters · filed 2025-02-12 | $4.72M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-12-31 | $725.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $3.49M derived: sum of 2 quarters · filed 2025-02-12 | $3.49M derived: sum of 3 quarters · filed 2025-02-12 | $13.61M 10-K · filed 2025-02-12 |
| 2023-09-30 | $2.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-25 | $2.77M derived: sum of 2 quarters · filed 2023-10-25 | $12.88M 10-Q · filed 2023-10-25 | $24.88M derived: sum of 4 quarters · filed 2024-02-21 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-26 | $10.12M 10-Q · filed 2023-07-26 | $22.12M derived: sum of 3 quarters · filed 2024-02-21 | $30.45M derived: sum of 4 quarters · filed 2024-02-21 |
| 2023-03-31 | $10.12M 10-Q · filed 2023-04-26 | $22.12M derived: sum of 2 quarters · filed 2024-02-21 | $30.45M derived: sum of 3 quarters · filed 2024-02-21 | $40.88M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $20.34M derived: sum of 2 quarters · filed 2024-02-21 | $30.77M derived: sum of 3 quarters · filed 2024-02-21 | $42.22M 10-K · filed 2024-02-21 |
| 2022-09-30 | $8.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $18.76M derived: sum of 2 quarters · filed 2022-11-02 | $30.21M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $21.88M 10-Q · filed 2022-07-27 | ||
| 2022-03-31 | $11.45M 10-Q · filed 2022-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |